Pathophysiologic aspects of systemic sclerosis;Patofysiologiske aspekter ved systemisk sklerose

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 19, 2005, Pages 2622-2623

  Gran, Jan Tore ^a   Molberg, Øyvind ^a   Midtvedt, Øyvind ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; TRANSFORMING GROWTH FACTOR BETA;

EXTRACELLULAR MATRIX; HUMAN; MEDICAL LITERATURE; PATHOPHYSIOLOGY; REVIEW; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

ENDOTHELIN-1; ENDOTHELINS; FIBROBLASTS; GROWTH SUBSTANCES; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 26944431596     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Mayes MD, Reveille JD. Epidemiology, demographics, and genetics. I: Clements PJ, Furst DE, red. Systemic sclerosis. 2. utg. Kap. 1. Philadelphia: Lippincott, Williams and Wilkins, 2003: 1-15.
2. Koh ET, Lee P, Gladman DD et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. J Rheumatol 1996; 35: 989-93.
3. Jiminez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.
4. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004; 50: 1721-33.
5. Lambert NC, Erickson TD, Yan Z et al. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies on healthy women and women with scleroderma. Arthritis Rheum 2004; 50: 906-14.
6. Sawaya HHB, Jiminez SA, Artlett CM. Quantification of fetal microchimeric cells in clinically affected and unaffected skin of patients with systemic sclerosis. Rheumatology 2004; 43: 965-8.
7. Burastero SE, Galbiati S, Vassallo A et al. Cellular microchimerism as a lifelong physiologic status in parous women. Arthritis Rheum 2003; 48: 1109-16.
8. Smith EA. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1992; 4: 869-77.
9. Ihn H. Pathogenesis of fibrosis: role of TGFβ and CTGF. Curr Opin Rheumatol 2002; 14: 681-5.
10. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15: 772-7.
11. Kubo M, Ihn H, Yamane K, Kamaki K. Upregulated expression of transforming growth factor β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis J Rheumatol 2002; 29: 2558-64.
12. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: rationale, current status and the future. Curr Opin Rheumatol 2002; 14: 717-22.
13. Denton CP, Abraham DJ. Transforming growth factor âand connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13: 505-11.
14. Kulozik M, Hogg B, Lankat-Buttgereit B et al. Colocalization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86: 917-22.
15. Highley H, Persichitte K, Chu S et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994; 37: 278-88.
16. Querfeld C, Eckes B, Huerkamp C et al. Expression of TGF-beta1, - beta2, and beta3 in localized and systemic sclerosis. J Dermatol Sci 1999; 21: 13-22.
17. Stratton R, Xu S, Martini G, Holme A et al. Ilioprost suppresses connective growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108: 241-50.
18. Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
19. Igarashi A, Nashiro K, Kikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
20. Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 1997; 29: 79-89.
21. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
22. Shi-wen X, Denton CP, Dashwood MR et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001; 116: 417-25.
23. Morelli S, Ferri C, Di Fransesco L et al. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 1995; 54: 730-4.
24. Danese C, Parlapiano C, Zavattaro E et al. Plasma levels during cold stress in scleroderma patients. Angiology 1997; 48: 965-8.
25. Kuroda K, Shinkai H. Decorin and glycosaminoglycan synthesis in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 481-5.
26. Xu S, Denton CP, Holmes A et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1988; 31 (suppl. 1): S360-3.
27. Haynes WG, Ferro CJ, O'Kane KPJ et al. Systemic endothelin blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-70.
28. Tabata H, Yamakage A, Yamasaki S. Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunelectron microscopic study. Int J Dermatol 1997; 36: 272-5.
29. Vancheeswaran R, Azam A, Black CM. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994; 21: 1268-76.
30. Kawaguchi Y, Suzuki K, Hara M et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53: 506-10.
31. Hocher B, Schwartz A, Fagan KA et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23: 19-26.
32. Mulder P, Richards V, Derumeaux G et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-82.
33. Boffa JJ, Tharaux PL, Dussaule JC et al. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37 (suppl 2): 490-6.
34. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonal arterial hypertension. N Engl J Med 2002; 346: 896-903.
35. Erratum: N Engl J Med 2002; 346: 1258.
36. Denton CP, Korn JH. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 2003; 1: 12-6.